Minh Chau Thi Pham

Array ( [id] => 19793525 [patent_doc_number] => 12234459 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-25 [patent_title] => Methods of treating cancer and/or enhancing sensitivity to cancer treatment by increasing tumor mutation burden or tumor indels [patent_app_type] => utility [patent_app_number] => 16/757583 [patent_app_country] => US [patent_app_date] => 2018-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 11 [patent_no_of_words] => 14043 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16916244 [patent_doc_number] => 20210189336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => BITE-ACTIVATED CAR-T CELLS [patent_app_type] => utility [patent_app_number] => 16/757522 [patent_app_country] => US [patent_app_date] => 2018-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14273865 [patent_doc_number] => 20190134217 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS [patent_app_type] => utility [patent_app_number] => 16/158164 [patent_app_country] => US [patent_app_date] => 2018-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25259 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16158164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14775047 [patent_doc_number] => 20190262421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => MODULATORS OF SYNDECAN-2 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/155732 [patent_app_country] => US [patent_app_date] => 2018-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33093 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16155732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19579860 [patent_doc_number] => 12145956 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-19 [patent_title] => Programmable polymeric drugs [patent_app_type] => utility [patent_app_number] => 16/639496 [patent_app_country] => US [patent_app_date] => 2018-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 22139 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 322 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14156475 [patent_doc_number] => 20190105340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => METHODS AND COMPOSITIONS FOR TARGETING VASCULAR MIMICRY [patent_app_type] => utility [patent_app_number] => 16/152080 [patent_app_country] => US [patent_app_date] => 2018-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17687 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16152080 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13867467 [patent_doc_number] => 20190030074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => Method of Ex Vivo Enhancement of Immune Cell Activity for Cancer Immunotherapy with a Small Molecule Ablative Compound [patent_app_type] => utility [patent_app_number] => 16/149468 [patent_app_country] => US [patent_app_date] => 2018-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12745 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16149468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14158807 [patent_doc_number] => 20190106506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/140089 [patent_app_country] => US [patent_app_date] => 2018-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16140089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671395 [patent_doc_number] => 20210060158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 16/644159 [patent_app_country] => US [patent_app_date] => 2018-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16644159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14040551 [patent_doc_number] => 20190076382 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => Targeted Treatment Of Anerobic Cancer [patent_app_type] => utility [patent_app_number] => 16/129051 [patent_app_country] => US [patent_app_date] => 2018-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29719 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16129051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15163337 [patent_doc_number] => 10487149 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-26 [patent_title] => Nucleic acid-polypeptide compositions and uses thereof [patent_app_type] => utility [patent_app_number] => 16/129694 [patent_app_country] => US [patent_app_date] => 2018-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 136 [patent_figures_cnt] => 141 [patent_no_of_words] => 96080 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16129694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733269 [patent_doc_number] => 20180371102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/128440 [patent_app_country] => US [patent_app_date] => 2018-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 95768 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16128440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17363592 [patent_doc_number] => 11230609 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-25 [patent_title] => Humanised anti kallikrein-2 antibody [patent_app_type] => utility [patent_app_number] => 16/117522 [patent_app_country] => US [patent_app_date] => 2018-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 21 [patent_no_of_words] => 19089 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16117522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16468210 [patent_doc_number] => 20200369747 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => METHODS OF INACTIVATING VIRAL CONTAMINANTS [patent_app_type] => utility [patent_app_number] => 16/641281 [patent_app_country] => US [patent_app_date] => 2018-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16641281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18133925 [patent_doc_number] => 11559574 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Whole-cell cancer vaccines and methods for selection thereof [patent_app_type] => utility [patent_app_number] => 16/110317 [patent_app_country] => US [patent_app_date] => 2018-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 38 [patent_no_of_words] => 49673 [patent_no_of_claims] => 81 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16110317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13625371 [patent_doc_number] => 20180364237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => Monitoring Cancer Stem Cells [patent_app_type] => utility [patent_app_number] => 16/109122 [patent_app_country] => US [patent_app_date] => 2018-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16109122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612234 [patent_doc_number] => 20210030887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => NON-NATURAL AMATOXIN-TYPE ANTIBODY CONJUGATE [patent_app_type] => utility [patent_app_number] => 16/975406 [patent_app_country] => US [patent_app_date] => 2018-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6537 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16975406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18302074 [patent_doc_number] => 11623965 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-11 [patent_title] => Prodruggable antibodies, prodrugs thereof, and methods of use and making [patent_app_type] => utility [patent_app_number] => 16/103654 [patent_app_country] => US [patent_app_date] => 2018-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 11673 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16103654 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17267542 [patent_doc_number] => 11192954 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Compounds and methods for the treatment of TROP2 positive diseases [patent_app_type] => utility [patent_app_number] => 16/100995 [patent_app_country] => US [patent_app_date] => 2018-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 28 [patent_no_of_words] => 13704 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16100995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733243 [patent_doc_number] => 20180371089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => ASYMMETRIC HETERODIMERIC FC-SCFV FUSION ANTI-GLOBO H AND ANTI-CD3 BISPECIFIC ANTIBODY AND USES THEREOF IN CANER THERAPY [patent_app_type] => utility [patent_app_number] => 16/016525 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6442 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16016525 [rel_patent_id] =>[rel_patent_doc_number] =>)